Viral Vector Manufacturing Market Introduction & Overview

Viral vectors are tools that are commonly utilized by molecular biologists to deliver genetic material to a particular cell. This process can be performed inside the living organism or in the cell culture. Therefore, these viruses have evolved sophisticated molecular mechanisms to transmit their genomes efficiently inside the cells that they infect. Additionally, in molecular biology research, viral vectors are utilized for the development of vaccines and gene therapy.

The viral vector manufacturing market is driven by factors such as the rising prevalence of target diseases such as tuberculosis, diphtheria, poliomyelitis, measles, pertussis, tetanus etc. Also rising prevalence cancer, infectious diseases & disorders, the increasing number of clinical studies, the availability of funding for the development of gene therapy, and ongoing research on gene &cell therapies based on viral vectors. The COVID-19 pandemic that is caused by SARS-CoV-2 is predicted to have a long-term effect on the viral vector manufacturing market.Consequently, companies in the viral vector manufacturing market are increasing their efforts to get theirhands on resources that they can capitalize on to minimize itsimpending consequences. However, challenges associated with viral vector production &manufacturing, the presence of strict regulatory policies, and risks associated with viral vectors may hinder the growth of the viral vector industry over the forecast period.

The global viral vector manufacturing market can be segmented into type, disease indication, application, end user,and region.

Viral Vector Manufacturing Market By Type

Based ontype, the market is segmented into adenoviral vectors, retroviral vectors, adeno-associated viral vectors, and others.The adeno-associated viral vector manufacturing segment is expected to grow at the highest CAGR during the forecast period, as it finds applications in most gene therapies based on cells. Adenoviral vectors have a wide range of activities and are capable of supplying both dividing and non-dividing cells with nucleic acids.Such factorsmay limittheir utilizationin basic research; however,they areoften used in vitro. Adenoviral vectors frequently precipitate immune destruction of the cells when used in vivo, which also restricts their functionality.

Viral Vector Manufacturing Market By Disease Indication

Based on disease indication, the market can be segmented intocancer, genetic disorders, infectious disease, and others.The cancer segmentaccounted for the largestmarket share during 2019. This large sharecan be attributed to increasing cancer research related to viral vector gene therapies.Viral vectors may generate tumor antigens (proteins found in a tumor cell) to activate the body's immune response to the antitumor.Viral vectors are also used to hold genes which are utilized to transform cancer cells into normal cells.

Viral Vector Manufacturing Market By Application

Based on the application, the market can be segmented into vaccinology and gene therapy.The gene therapy segment is expected to grow at the highest rate during the forecast period. This segmentis driven by the availability of successful viral vector gene therapies for genetic diseases and cancers, on going work on viral vector gene therapies, and the recent approval of several viral vector gene therapies.

Viral Vector Manufacturing Market By End-user

Based on end-user, the market can be segmented into research institutions and pharmaceutical and biotechnological companies.The pharmaceutical and biotechnological companies segment accounted for the largest share of the global viral vector manufacturing market in 2019.The successful introduction of viral vector gene therapies and a strong pipeline of suchtherapies will contribute significantly to the growth of this segment during the forecast period. Apart from this, the U.S.FDA granted approvalsto cell and gene therapy for cardiovascular diseases, cancerdrugs, and genetic diseases.

Viral Vector Manufacturing Market By Region

Based on region, the market can be segmented into North America, Europe, Asia-Pacific, and the Rest of the World (ROW). North America is expected to dominate the market during the forecast periodowing tothe increased production of viral vectors as a result of regional developments and increased research activities. According to the American Cancer Society, 6 out of 10 patients are getting curedofprostate cancerand this figure has grown to 2.9 million in 2019. Also,adenovirus vectors are utilized in cancer gene therapy, and foreign antigens are expressed in vaccines.

The prominent players in the viral vector manufacturing market are Spark Therapeutics, Inc., Brammer Bio, Merck KGaA, Lonza, Oxford BioMedica, uniQure, CGT Catapult, Novasep, Creative Biogene, andThermo Fisher Scientific Inc., among others.